DMT is produced naturally in the body and acts on serotonin receptor subtypes that are broadly expressed in many tissues, however the impact of DMT outside of its obvious psychotropic effects on the brain are little understood. PharmaDrug has formed an impressive working group of renowned academic researchers to investigate the underpinnings of how DMT impacts health and disease.
Partnered with the University of Michigan to study the role of endogenous DMT in the brain
Enters Into a Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study
Sponsored research agreement with the Terasaki Institute to develop a novel ocular drug delivery for DMT in eye diseases
Obtained orphan drug designation for DMT to treat ischemia-reperfusion injury in organ transplant patients
Based on compelling 3rd party data examining the impact of serotonin
signalling in the eye, PharmaDrug is pursuing an R&D strategy for DMT
to treat glaucoma.
The impact of serotonin receptor activation has been implicated in healthy regulation of
pressure in the eye. Increased pressure in the eye, a hallmark of glaucoma, results in
damage to the optic nerve and irreversible vision loss. PharmaDrug is using its deep
knowledge about DMT-driven activation of serotonin receptors in the eye to formulate
transformative medications to treat and prevent vision loss.